Safety of Posaconazole and Sirolimus Coadministration in Allogeneic Hematopoietic Stem Cell Transplants
David W. Kubiak(Harvard University), Francisco M. Marty(Brigham and Women's Hospital), Sarah P. Hammond(Dana-Farber Cancer Institute), Sophia Koo(Dana-Farber Brigham Cancer Center), Philippe Armand(Harvard University), Joseph H. Antin(Dana-Farber Cancer Institute), Lindsey R. Baden(Brigham and Women's Hospital)
Cited by 27
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k